Product category:
Contract research
News Release from: Lab21
Edited by the Laboratorytalk Editorial
Team on 21 January 2008
Diagnostic assays for healthcare and
environment
Following the appointment of CEO Graham Mullis, Lab 21 is focusing its products and services under two key areas: healthcare diagnostics including personalised medicine; and environmental diagnostics
Lab21, a UK-based company set up in 2005 to spearhead increased availability of state-of-the-art diagnostic tests for healthcare and environmental monitoring, says it is set to consolidate its strategy further in 2008, having built up an impressive portfolio of tests and services during 2007 The company operates from its two UK sites in Cambridge and Newmarket
This article was originally published on Laboratorytalk on 26 Jul 2005 at 8.00am (UK)
Related stories
Antiviral drug discovery and clinical trials
Array of spearhead tests and services available include lead identification and optimisation, resistance profiling, clinical candidate selection and selectivity evaluation in pre-clinical situations
Liver disease assessment service is 'breakthrough'
System substitutes for biopsy by using surrogate markers of liver disease that can be measured using simple blood tests
Graham Mullis, CEO of Lab21 said: "The recent announcement of NHS plans to increase diagnostic screening is excellent news for patients and underlines the global trend towards preventative and personalised medicine.
"Earlier, faster and more accurate diagnosis is now at the centre of healthcare regimes.
"This means for Lab21, with an ever growing portfolio of tests and partnerships we are well placed to deliver improved healthcare.
"In addition, an increased focus on environmental monitoring aligns well with our environmental services - Lab21 is well positioned to develop into a leading provider of healthcare and environmental diagnostics.
"I am confident that with our new executive management team we are well placed to drive the business forward.
2008 is set to be an exciting and dynamic year for Lab21 and its shareholders," he added.
During 2008 the company will be recruiting to expand its sales and technical teams, in line with the expansion in its offerings.
Lab21 starts 2008 refocused with some early success already under its belt.
"December 2007 was an excellent month for Lab-21 with the best sales performance in the history of the company," said Maddy Kennedy, chief financial officer, adding, "During 2008 we will be exploring options to further expand the company through both alliances and acquisitions, and to ensure the company has the finances available to deliver on its strategic objectives and to grow shareholder value.".
• Lab21: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
